• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects.奥氮平在中国受试者和高加索受试者中的药代动力学相似。
Br J Clin Pharmacol. 2003 Aug;56(2):184-7. doi: 10.1046/j.1365-2125.2003.01857.x.
2
Influence of fluoxetine on olanzapine pharmacokinetics.氟西汀对奥氮平药代动力学的影响。
AAPS PharmSci. 2002;4(2):E11. doi: 10.1208/ps040211.
3
[Monitoring of serum olanzapine during antipsychotic treatment].[抗精神病治疗期间血清奥氮平的监测]
Ugeskr Laeger. 2000 Sep 4;162(36):4802-5.
4
Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia.奥氮平在患有儿童期起病精神分裂症的儿科和青少年住院患者中的药代动力学。
J Clin Psychopharmacol. 2000 Apr;20(2):220-5. doi: 10.1097/00004714-200004000-00015.
5
Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes.奥氮平在人体内的处置与CYP1A2和CYP2D6的表型无关。
Eur J Clin Pharmacol. 2001 Sep;57(6-7):493-7. doi: 10.1007/s002280100343.
6
Olanzapine. Pharmacokinetic and pharmacodynamic profile.奥氮平。药代动力学和药效学概况。
Clin Pharmacokinet. 1999 Sep;37(3):177-93. doi: 10.2165/00003088-199937030-00001.
7
Differential olanzapine plasma concentrations by sex in a fixed-dose study.
Schizophr Res. 1999 Nov 30;40(2):101-4. doi: 10.1016/s0920-9964(99)00053-5.
8
Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers.利托那韦对健康志愿者中奥氮平药代动力学的影响。
J Clin Psychopharmacol. 2002 Aug;22(4):366-70. doi: 10.1097/00004714-200208000-00006.
9
[Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring].奥氮平：药理学、药代动力学及治疗药物监测
Fortschr Neurol Psychiatr. 2001 Nov;69(11):510-7. doi: 10.1055/s-2001-18381.
10
Disposition of olanzapine in Chinese schizophrenic patients.奥氮平在中国精神分裂症患者中的处置情况。
Int J Clin Pharmacol Ther. 2000 Oct;38(10):482-5. doi: 10.5414/cpp38482.

引用本文的文献

1
Reflections on the Lack of Consideration of Ethnic Ancestry to Stratify Clozapine Dosing.关于未考虑种族血统来分层氯氮平剂量的思考。
Psychiatry Investig. 2023 Mar;20(3):183-195. doi: 10.30773/pi.2022.0293. Epub 2023 Feb 28.
2
Racial/Ethnic Differences in the Pharmacokinetics of Antipsychotics: Focusing on East Asians.抗精神病药物药代动力学的种族/民族差异：以东亚人为重点。
J Pers Med. 2022 Aug 24;12(9):1362. doi: 10.3390/jpm12091362.
3
The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients.吸烟、性别、感染和合并用药对中国精神科患者奥氮平口腔崩解片药代动力学的影响：一项群体药代动力学模型研究。
Eur J Drug Metab Pharmacokinet. 2021 May;46(3):353-371. doi: 10.1007/s13318-021-00673-5. Epub 2021 Mar 6.
4
Population pharmacokinetics of olanzapine in children.奥氮平在儿童中的群体药代动力学。
Br J Clin Pharmacol. 2021 Feb;87(2):542-554. doi: 10.1111/bcp.14414. Epub 2020 Jul 5.
5
Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.应用基于生理学的药代动力学模型和模拟预测个体患者的奥氮平暴露量。
Br J Clin Pharmacol. 2018 Mar;84(3):462-476. doi: 10.1111/bcp.13480. Epub 2018 Jan 11.
6
Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis.基于临床治疗药物监测数据并借助Meta分析的奥氮平在中国精神病患者中的群体药代动力学分析
Eur J Clin Pharmacol. 2016 Aug;72(8):933-44. doi: 10.1007/s00228-016-2040-2. Epub 2016 Apr 27.
7
Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review.奥氮平用于中国精神分裂症或双相情感障碍患者：一项系统文献综述
Neuropsychiatr Dis Treat. 2014 May 16;10:841-64. doi: 10.2147/NDT.S58096. eCollection 2014.
8
Method of variability optimization in pharmacokinetic data analysis.药代动力学数据分析中的变异性优化方法。
Eur J Drug Metab Pharmacokinet. 2014 Jun;39(2):111-9. doi: 10.1007/s13318-013-0145-x. Epub 2013 Jun 19.
9
Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?奥氮平治疗精神分裂症是否需要临床药代动力学监测？
Clin Pharmacokinet. 2011 Jul;50(7):415-28. doi: 10.2165/11587240-000000000-00000.

本文引用的文献

1
Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes.通过cDNA表达的人尿苷二磷酸葡萄糖醛酸基转移酶和人肝微粒体对奥氮平进行葡萄糖醛酸化作用。
Hum Psychopharmacol. 2002 Jul;17(5):233-8. doi: 10.1002/hup.403.
2
Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service.
Ther Drug Monit. 2001 Aug;23(4):410-3. doi: 10.1097/00007691-200108000-00015.
3
Olanzapine. Pharmacokinetic and pharmacodynamic profile.奥氮平。药代动力学和药效学概况。
Clin Pharmacokinet. 1999 Sep;37(3):177-93. doi: 10.2165/00003088-199937030-00001.
4
Human cytochrome P4501A2.人类细胞色素P4501A2。
IARC Sci Publ. 1999(148):173-95.
5
Review of recent clinical studies with olanzapine.
Br J Psychiatry Suppl. 1999(37):30-5.
6
A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism.卡马西平与奥氮平之间的药代动力学相互作用：对可能机制的观察
Eur J Clin Pharmacol. 1998 Oct;54(8):639-43. doi: 10.1007/s002280050527.
7
Influence of race or ethnicity on pharmacokinetics of drugs.种族或民族对药物药代动力学的影响。
J Pharm Sci. 1997 Dec;86(12):1328-33. doi: 10.1021/js9702168.
8
The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate.种族因素和性别对CYP1A2介导的药物处置的影响：以非那西丁为标记底物，在白种人和中国受试者中进行的比较研究。
Ther Drug Monit. 1996 Oct;18(5):586-91. doi: 10.1097/00007691-199610000-00011.
9
Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection.利用反相高效液相色谱-电化学检测法分析人血浆中的奥氮平。
J Chromatogr B Biomed Appl. 1995 Jun 9;668(1):85-90. doi: 10.1016/0378-4347(95)00061-m.
10
Diazepam effects and kinetics in Caucasians and Orientals.地西泮在白种人和东方人中的效应与动力学。
Clin Pharmacol Ther. 1981 Jun;29(6):749-56. doi: 10.1038/clpt.1981.106.

奥氮平在中国受试者和高加索受试者中的药代动力学相似。

Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects.

作者信息

Sathirakul Korbtham, Chan Clark, Teng Leyan, Bergstrom Richard F, Yeo Kwee Poo, Wise Stephen D

机构信息

Lilly-NUS Centre for Clinical Pharmacology, National University of Singapore, Singapore.

出版信息

Br J Clin Pharmacol. 2003 Aug;56(2):184-7. doi: 10.1046/j.1365-2125.2003.01857.x.

DOI:10.1046/j.1365-2125.2003.01857.x
PMID:12895191
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1884282/
Abstract

AIM

To compare the pharmacokinetic profiles and dose proportionality of olanzapine in Chinese and Caucasian subjects.

METHODS

Randomized, three-period study with 12 Chinese and 12 Caucasian, healthy, male subjects administered 2.5, 5 and 10 mg olanzapine. Noncompartmental pharmacokinetic parameters were derived.

RESULTS

No statistically significant racial differences in the weight-normalized pharmacokinetic parameters were observed except for Vz/Fnorm, which was 17% lower at the 5- and 10-mg dose in the Chinese group (95% confidence interval 8.49, 10.1 and 8.05, 9.73, respectively), compared with the Caucasian group (9.53, 12.8 and 9.39, 12.0, respectively). Olanzapine's pharmacokinetics were linear and dose proportional in both racial groups.

CONCLUSION

The pharmacokinetics of olanzapine are similar in both Chinese and Caucasian racial groups.

摘要

目的

比较奥氮平在中国受试者和高加索受试者中的药代动力学特征及剂量比例关系。

方法

采用随机、三周期研究，12名中国健康男性受试者和12名高加索健康男性受试者服用2.5、5和10毫克奥氮平。得出非房室药代动力学参数。

结果

除Vz/Fnorm外，体重标准化药代动力学参数未观察到统计学上的显著种族差异。中国组在5毫克和10毫克剂量时，Vz/Fnorm分别比高加索组低17%（95%置信区间分别为8.49, 10.1和8.05, 9.73），而高加索组分别为9.53, 12.8和9.39, 12.0。奥氮平在两个种族组中的药代动力学均呈线性且与剂量成比例。

结论

奥氮平在中国种族组和高加索种族组中的药代动力学相似。